ออฟไลน์ด้วยแอป Player FM !
5-Minute Check In: Evaluating the Use of Resmetirom in Patients with NASH and Liver Fibrosis
Manage episode 418455867 series 3291352
First-of-its-kind medication shows promise for liver disease patients
- Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is estimated to affect nearly one-quarter of adults in the United States. Nonalcoholic steatohepatitis (NASH) is a form of MASLD that can cause liver fibrosis, cirrhosis, liver failure, and liver cancer. It is one of the most common reasons why patients need liver transplants.
- The FDA recently granted accelerated approval to resmetirom, the first medication to treat nonalcoholic steatohepatitis (NASH) and liver fibrosis.
- Prior to the FDA approval, there were no approved drugs to treat this disease
In this 5-minute check in, we review the promising phase 3 data from a randomized trial that led to FDA approval including the results, the implications for patient care, and the potential to transform the landscape of NASH management
Guest: Dr. Justin Reynolds, Associate Professor, Creighton University School of Medicine, Gastroenterologist and Transplant Hepatologist, St Joseph's Hospital and Medical Center Transplant Center in Phoenix, Arizona.
110 ตอน
5-Minute Check In: Evaluating the Use of Resmetirom in Patients with NASH and Liver Fibrosis
5-Minute Clinical Update and Grand Rounds with Dr. Thomas McGinn
Manage episode 418455867 series 3291352
First-of-its-kind medication shows promise for liver disease patients
- Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is estimated to affect nearly one-quarter of adults in the United States. Nonalcoholic steatohepatitis (NASH) is a form of MASLD that can cause liver fibrosis, cirrhosis, liver failure, and liver cancer. It is one of the most common reasons why patients need liver transplants.
- The FDA recently granted accelerated approval to resmetirom, the first medication to treat nonalcoholic steatohepatitis (NASH) and liver fibrosis.
- Prior to the FDA approval, there were no approved drugs to treat this disease
In this 5-minute check in, we review the promising phase 3 data from a randomized trial that led to FDA approval including the results, the implications for patient care, and the potential to transform the landscape of NASH management
Guest: Dr. Justin Reynolds, Associate Professor, Creighton University School of Medicine, Gastroenterologist and Transplant Hepatologist, St Joseph's Hospital and Medical Center Transplant Center in Phoenix, Arizona.
110 ตอน
Semua episod
×1 Myth Busting: Is exercise = to other treatments to help depression? Do tattoos cause lymphoma? 5:55
1 Virtual Grand Rounds/Clinical Update: Fast Track Insights: Rapid Review of Impactful Articles 53:00
1 Virtual Grand Rounds: Implementation of Race-Neutral GLI Equation for Pulmonary Function Tests 50:08
1 Virtual Grand Rounds/Clinical Update: Game-Changing Updates in Management of Sickle Cell Disease 1:03:04
ขอต้อนรับสู่ Player FM!
Player FM กำลังหาเว็บ